Key Decisions in HIV Care: Considering the Use of Proviral DNA Genotyping to Inform ART Choice

In this episode, John D. Baxter, MD, explores recommendations and data on the use of proviral DNA genotyping to inform antiretroviral therapy (ART) choice for patients who are treatment experienced.Listen as he gives his perspectives on:US Department of Health and Human Services guideline recommendations on the use of proviral DNA genotypingUS Department of Health and Human Services guideline recommendations and supporting data on switching ART with viral suppression and underlying drug resistanceStudy 380-4030 on outcomes with bictegravir- and dolutegravir-based ART in patients with preexisting nucleos(t)ide reverse-transcriptase inhibitor resistanceThe BRAAVE 2020 study on switching to bictegravir/emtricitabine/tenofovir alafenamide in Black persons with HIV, some of whom had baseline ART resistanceBetween-class ART switches with underlying resistanceSusceptibility of tenofovir disoproxil fumarate and abacavir with thymidine analogue mutationsPresenter:John D. Baxter, MDProfessor of MedicineDivision of Infectious DiseasesDepartment of PathologyCooper Medical School of Rowan UniversityHead, Division of Infectious DiseasesCooper University Health CareCamden, New JerseyFollow along with the slides at:https://bit.ly/3HmkSLcSee the entire program at: https://bit.ly/3fOl0XX Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There are no comments yet.

Please log in to write the first comment.